Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer.

Publication

Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer.

Journal Paper/Review - May 15, 2023

Omlin Aurelius, Cathomas Richard, von Amsberg Gunhild, Reuter Christoph, Feyerabend Susan, Loidl Wolfgang, Boegemann Martin, Lorch Anja, Heidenreich Axel, Tsaur Igor, Larcher-Senn Julian, Buck Stefan A J, Mathijssen Ron H J, Jaehde Ulrich, Gillessen Silke, Jörger Markus

Citation

Omlin A, Cathomas R, von Amsberg G, Reuter C, Feyerabend S, Loidl W, Boegemann M, Lorch A, Heidenreich A, Tsaur I, Larcher-Senn J, Buck S, Mathijssen R, Jaehde U, Gillessen S, Jörger M. Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 2023; 29:1887-1893.

Type

Journal Paper/Review (English)

Journal

Clin Cancer Res 2023; 29

Publication Date

May 15, 2023

Issn Electronic

1557-3265

Pages

1887-1893

Brief description/objective

There is ongoing controversy about the recommended dose of cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).